GlobeNewswire Inc. · Jun 28, 2023
Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
ER
NASDAQ · ERYP
ERYTECH Pharma S.A.
Healthcare · Biotechnology
$0.78
Up+$0.01 (+1.30%)
Updated Sep 12, 2026, 9:55 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 47.38M
- P/E ratio
- -0.02
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 3.21K
- Avg. volume
- 150.83K
Price performance
ERYP price history
1M range · 0 trading sessions · Daily adjusted prices
ERYP does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest ERYP news
The latest Smart Investors Daily articles mentioning ERYP.
Stock researchCompany · Overview
ERYP research
Overview
Company profile and research snapshot.
Company profile
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 5, 2017 | Cowen & Co. | Outperform | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Jun 28, 2023
Phaxiam Therapeutics annonce son nouveau code mnémonique sur Euronext et Nasdaq : PHXM
Phaxiam Therapeutics annonce son nouveau code mnémonique sur Euronext et Nasdaq : PHXM
GlobeNewswire Inc. · Jun 26, 2023
ERYTECH et PHERECYDES annoncent leur fusion pour former PHAXIAM Therapeutics
ERYTECH et PHERECYDES annoncent leur fusion pour former PHAXIAM Therapeutics
GlobeNewswire Inc. · Jun 26, 2023
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
